c-Abl Mediates α-Synuclein Toxicity: A Promising Therapeutic Target in Parkinson's Disease and α-Synucleinopathies

被引：0
|
作者：
Brahmachari, S. [1 ,2 ,3 ]
Mao, X. [1 ,2 ,3 ]
Karuppagounder, S. S. [1 ,2 ,3 ]
Lee, Y. [1 ,2 ,3 ]
Dawson, V. L. [1 ,2 ,3 ,4 ,5 ,6 ]
Ko, H. S. [1 ,2 ,7 ]
Dawson, T. M. [1 ,2 ,6 ,7 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[3] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA USA
[4] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Stem Cell Programs, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA
[6] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA
[7] Diana Helis Henry Med Res Fdn, New Orleans, LA USA
来源：
CELL TRANSPLANTATION | 2014年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
引用
收藏
页码：764 / 764
页数：1
相关论文
共 50 条
  • [1] Targeting α-synuclein and c-Abl in Parkinson's disease
    Xiao, Bin
    Tan, Eng-King
    TRENDS IN MOLECULAR MEDICINE, 2023, 29 (11) : 883 - 885
  • [2] C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
    Abushouk, Abdelrahman Ibrahim
    Negida, Ahmed
    Elshenawy, Rasha Abdelsalam
    Zein, Hossam
    Hammad, Ali M.
    Menshawy, Ahmed
    Mohamed, Wael M. Y.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2018, 17 (01) : 14 - 21
  • [3] c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential
    Brahmachari, Saurav
    Karuppagounder, Senthilkumar S.
    Ge, Preston
    Lee, Saebom
    Dawson, Valina L.
    Dawson, Ted M.
    Ko, Han Seok
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (04) : 589 - 601
  • [4] Evaluation of c-Abl tyrosine kinase mediated regulation of parkin as therapeutic target for Parkinson's disease
    Imam, S. Z.
    Sriram, S.
    Ko, H. S.
    Pearson, D. W.
    Valente, A. J.
    Savitt, J. M.
    Andres-Mateos, E.
    Trinkaus, D. B.
    Pletnikova, O.
    Troncoso, J. C.
    Yamamoto, A.
    Kahle, P. J.
    Ali, S. F.
    Dawson, V. L.
    Li, S.
    Roberts, J. L.
    Dawson, T. M.
    Clark, R. A.
    MOVEMENT DISORDERS, 2007, 22 : S100 - S100
  • [5] α-Synuclein: A therapeutic target for Parkinson's disease?
    Maguire-Zeiss, Kathleen A.
    PHARMACOLOGICAL RESEARCH, 2008, 58 (5-6) : 271 - 280
  • [6] c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
    Mahul-Mellier, Anne-Laure
    Fauvet, Bruno
    Gysbers, Amanda
    Dikiy, Igor
    Oueslati, Abid
    Georgeon, Sandrine
    Lamontanara, Allan J.
    Bisquertt, Alejandro
    Eliezer, David
    Masliah, Eliezer
    Halliday, Glenda
    Hantschel, Oliver
    Lashuel, Hilal A.
    HUMAN MOLECULAR GENETICS, 2014, 23 (11) : 2858 - 2879
  • [7] The c-Abl inhibitor in Parkinson disease
    Zhou, Zhi-Hua
    Wu, Yun-Fan
    Wang, Xue-min
    Han, Yong-Zhu
    NEUROLOGICAL SCIENCES, 2017, 38 (04) : 547 - 552
  • [8] The c-Abl inhibitor in Parkinson disease
    Zhi-Hua Zhou
    Yun-Fan Wu
    Xue-min Wang
    Yong-Zhu Han
    Neurological Sciences, 2017, 38 : 547 - 552
  • [9] Suppressing c-Abl in Parkinson disease
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (03) : 183 - 183
  • [10] Suppressing c-Abl in Parkinson disease
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2023, 22 : 183 - 183
12345